Phosphodiesterase 5 mechanisms and therapeutic applications

American Journal of Cardiology

Volumn 96, Issue 12 SUPPL. 2, 2005, Pages 29-31

  Burnett, Arthur L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

CLINICAL TRIAL; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; PENIS; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN DOMAIN; SEXUAL AROUSAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE;

EID: 29544437486     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.07.008     Document Type: Article

References (14)

1. T.F. Lue Erectile dysfunction N Engl J Med 342 2000 1802 1813
2. A.L. Burnett Novel nitric oxide signaling mechanisms regulate the erectile response Int J Impot Res 16 suppl 1 2004 S15 S19
3. S.H. Francis, I.V. Turko, J.D. Corbin Cyclic nucleotide phosphodiesterases relating structure and function Prog Nucleic Acid Res Mol Biol 65 2001 1 52
4. M. Shimizu-Albergine, S.D. Rybalkin, I.G. Rybalkina, R. Feil, W. Wolfsgruber, F. Hofmann, J.A. Beavo Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs) in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation J Neurosci 23 2003 6452 6459
5. J.D. Corbin Mechanisms of action of PDE5 inhibition in erectile dysfunction Int J Impot Res 16 suppl 1 2004 S4 S7
6. A.L. Burnett, H.C. Champion, M.A. Palese, T.J. Bivalacqua, M. Kramer, B. Musicki, P.L. Huang, J.M. Hare, D.A. Kass Mechanism of priapism dysregulation of downstream mediators of nitric oxide signal transduction J Urol 169 2003 305
7. R.C. Rosen, J.B. Kostis Overview of phosphodiesterase 5 inhibition in erectile dysfunction Am J Cardiol 92 2003 9M 18M
8. N.N. Kim Phosphodiesterase type 5 inhibitors a biochemical and clinical correlation survey Int J Impot Res 15 suppl 5 2003 S13 S19
9. A.D. Seftel Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles Clin Cardiol 27 4 suppl 1 2004 I14 I19
10. B.J. Sung, K.Y. Hwang, Y.H. Jeon, J.I. Lee, Y.S. Hoe, J.H. Kim, J. Moon, J.M. Yoon, Y.L. Hyun, E. Kim Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules Nature 425 2003 98 102
11. M.A. Blount, A. Beasley, R. Zoraghi, K.R. Sekhar, E.P. Bessay, S.H. Francis, J.D. Corbin Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation Mol Pharmacol 66 2004 144 152
12. B.K. Sastry, C. Narasimhan, N.K. Reddy, B.S. Raju Clinical efficacy of sildenafil in primary pulmonary hypertension a randomized, placebo-controlled, double-blind, crossover study J Am Coll Cardiol 43 2004 1149 1153
13. R. Shabsigh, J.M. Kaufman, C. Steidle, H. Padma-Nathan Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone J Urol 172 2004 658 663
14. A. Morelli, S. Filippi, R. Mancina, M. Luconi, L. Vignozzi, M. Marini, C. Orlando, G.B. Vannelli, A. Aversa, A. Natali Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa Endocrinology 145 2004 2253 2263